Ignite Creation Date:
2024-05-05 @ 11:13 PM
Last Modification Date:
2024-10-26 @ 10:30 AM
Study NCT ID:
NCT01286987
Status:
COMPLETED
Last Update Posted:
2019-01-10
First Post:
2011-01-26
Brief Title:
Study of Talazoparib a PARP Inhibitor in Patients With Advanced or Recurrent Solid Tumors
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 1 First In Human Single-arm Open-label Study Of Once A Day Orally Administered Talazoparib Bmn 673 In Patients With Advanced Or Recurrent Solid Tumors
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-arm open-label study to assess the safety pharmacokinetics pharmacodynamics and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies There will be 2 parts to the study a dose escalation phase in which the maximum tolerated dose will be defined and a dose expansion phase
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| C3441007 | OTHER | Alias Study Number | None |
| 2010-023062-40 | EUDRACT_NUMBER | None | None |